Sci2sci raises €1.2M for AI verification in biopharma

Berlin-based software startup sci2sci has raised €1.2 million in pre-seed funding. The round was co-led by Heliad and IBB Ventures, with participation from Robin Capital and Superangels.

Founded by Angelina Lesnikova and Valerii Kremnev, the company builds technology to organise and verify data for regulated industries. Its initial focus is the biopharma sector.

The Problem of Fragmented Data

In biopharma, critical research and regulatory information is often scattered. It lives in PDFs, spreadsheets, laboratory notes, and multiple disconnected systems. This fragmentation makes tracing findings back to their original sources difficult. The problem is acute during regulatory reviews and audits. AI tools can worsen the issue if they operate on incomplete or inconsistent data.

Building Trusted AI Infrastructure

Sci2sci's core product is called Integrity Cortex. It connects information from company documents, data stores, and AI outputs into a structured network. The system links claims to their sources and verifies citations and conclusions. It creates an auditable record designed to comply with 21 CFR Part 11, a key regulation for electronic records in life sciences.

Integrity Cortex is built on a framework named Parseltongue. Sci2sci open-sourced Parseltongue this year under the Apache 2.0 licence.

The company's second product is VectorCat. It acts as a data integration layer. VectorCat connects information stored across cloud storage, network drives, and laboratory systems. It does this without requiring companies to migrate their underlying data. The product creates a searchable catalogue accessible to both employees and AI applications.

The Model and the Governing Rule

Valerii Kremnev, co-founder and CTO of sci2sci, explained the company's philosophy to Tech.eu. He said their approach builds verification and traceability directly into AI workflows from the start.

“Instead of shipping capabilities first and patching trust and security afterward, we built Parseltongue and Integrity Cortex to permit only safe outputs,” Kremnev said. He used an analogy: “A model’s lockpicking skills are useless when there’s no door, and our software guarantees there is none.”

This describes the core rule governing AI deployment in their system. The model is constrained by infrastructure that mandates evidence and blocks unverified outputs.

Funding and Future Plans

Sci2sci is already working with customers in preclinical research, contract clinical research, and bioprocess operations. The new €1.2 million in funding will be used to expand the engineering team and deepen existing customer deployments. The company also aims to reach more biopharma clients.

A longer-term plan involves extending the Integrity Cortex platform into other heavily regulated industries. Banking is named as a next target sector. The funding round highlights current trends in AI investment, where infrastructure for trust and compliance in regulated fields is attracting capital.